Teva Shows Its Big Pharma Clout With $1.5bn Sanofi Deal
Israeli Firm Stepping Up Investments In Branded Space, Under CEO Francis
Teva has wrapped up an earlier deal with Sanofi that will see the French giant take command of its novel TL1A inhibitor currently in a Phase IIb study for ulcerative colitis and Crohn’s disease.
